OPPI appoints Anil Matai as Director-General

New Delhi: The Organisation of Pharmaceutical Producers of India (OPPI), which represents global research-based pharmaceutical companies, has appointed Anil Matai as its Director General.

Anil Matai, a seasoned general management professional, has extensive experience in the Life Sciences space having worked across MNCs including spearheading operations across Novartis India Ltd, GSK India, and Global Pharma, Dubai.

After superannuating as Managing Director of Zydus Healthcare Ltd, Anil was engaged as Senior Advisor – Life Sciences at IQVIA Consulting and Information Services India Pvt. Ltd., and most recently as Operating Partner at Jashvik Capital – a mid-market Private Equity Fund focused on Healthcare & Consumer sector. Anil has functioned on the boards of Zydus Healthcare Ltd., Bayer Zydus Pharma Private Ltd., Novartis Healthcare Private Ltd and Biochem Pharmaceutical Industries Ltd.

As an influential leader, his proven skillsets in operations leadership, collaborative working, stakeholder management, have contributed towards market-leading results. He has championed multi-million-dollar businesses and is proficient in unlocking company value by successfully executing growth strategies, institutionalizing controls, and enhancing productivity.

Welcoming Anil as the Director General, Suresh Pattathil, President, OPPI said, “I welcome Anil on board and am confident that with his breadth of experience, we will be able to lead OPPI to achieve its objective of bringing innovative drugs and new therapies for unmet medical needs and drive key advocacy efforts on IP, Innovation, Quality and other areas. He has been a strong voice for healthcare transformation in the country and under his leadership we will be able to optimize patient outcomes by creating an environment conducive to innovation and growth, engaging productively with Government stakeholders.”

Speaking on his appointment, Anil Matai said, “I am delighted to be a part of the OPPI family during a pivotal moment for healthcare in our nation. I am happy to say that OPPI’s focus on importance of innovation, digitization and quality to drive impact in healthcare, aligns with the Government’s vision for India@100. OPPI will continue to drive policy and advocacy discussions with the Government and endeavor to work together with various stakeholders on industry-related issues, to implement sustainable and patient centric solutions. I look forward to collaborating with the various stakeholders including the Government, Industry, Academia to make a positive impact on patient well-being; in alignment with OPPI’s vision of “Bharat Ke Liye”. I express my gratitude to the members of OPPI’s Executive Committee for entrusting me with this responsibility.”